Cancer BiologybioRxiv
Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2
V. Barbarino, S. Henschke, S. Blakemore…·C. P. Pallasch
The paper shows ibrutinib enhances macrophage-mediated antibody-dependent cellular phagocytosis in B-cell lymphoma by inhibiting JAK2, improving treatment outcomes.
DOI 10.3390/cancers12082303